Wegovy and Visceral Fat: Separating Myth from Evidence

The myth: Wegovy melts visceral fat while leaving everything else alone

It's a persistent idea, that GLP-1 medicines are somehow able to seek out dangerous internal fat and dissolve it, while preserving muscle and subcutaneous tissue. That framing sells well on social media. It is also wrong in its specifics, even if the outcome it describes is real enough.

Wegovy reduces overall body weight. When body weight falls, visceral fat does tend to reduce disproportionately compared to total fat mass, a pattern seen with caloric-deficit interventions generally, and one amplified by the scale of weight loss Wegovy produces. The STEP 1 trial, published in the New England Journal of Medicine, found that adults treated with semaglutide 2.4mg lost around 15% of body weight on average over 68 weeks. Crucially, waist circumference fell by around 13.5 cm in the treatment group, a clinically meaningful signal for visceral fat reduction, since waist circumference is the most practical proxy measure available outside a research scanner.

So Wegovy does reach visceral fat. It just does so through the ordinary physics of sustained caloric deficit at a scale most people cannot achieve by lifestyle change alone. That is not a lesser result. It is, if anything, a more honest one.

Why visceral fat specifically responds to semaglutide's effects

Visceral adipose tissue is metabolically busier than the fat just under the skin. It is more sensitive to hormonal signals, drains directly into the portal circulation, and is released relatively readily during an energy deficit. This is why reductions in waist circumference often appear earlier, and proportionally larger, than reductions in overall body fat percentage on imaging studies.

Semaglutide works by activating GLP-1 receptors, reducing appetite, slowing how quickly food leaves the stomach, and increasing feelings of fullness after smaller meals. The result is a consistent and significant energy deficit over months, which is exactly the stimulus visceral fat responds to. For more on how the medicine works mechanically, our semaglutide overview covers the receptor-level detail.

Research has also looked at imaging-confirmed visceral fat outcomes in semaglutide trials. Reductions in liver fat have been observed, which is relevant because hepatic steatosis (fat in the liver) is closely tied to visceral adiposity. The MHRA's approval of Wegovy for a form of fatty liver disease (MASH) in July 2026 reflects this body of evidence, though that indication is separate from the weight-management licence.

One practical note: a weekly injection taken from the fridge each morning becomes routine quickly. The habit-building that supports the lifestyle changes the medicine works alongside tends to follow from that regularity too.

What this means for cardiovascular and metabolic risk

Visceral fat is not just a cosmetic concern. High levels are independently associated with elevated cardiovascular risk, insulin resistance, type 2 diabetes, raised triglycerides and systemic inflammation. Reducing it has measurable consequences for health markers, not just for clothing size.

The SELECT trial, which examined semaglutide's cardiovascular effects in people with obesity and established cardiovascular disease, found a significant reduction in major cardiovascular events over about three years. While that trial was powered for cardiovascular endpoints rather than visceral fat specifically, the metabolic improvements associated with weight loss (including visceral fat reduction) are thought to contribute to that signal.

If you want to explore whether Wegovy helps with visceral fat specifically and what the evidence shows in practice, that page sets out the clinical picture in detail. For a closer look at the specific percentage reductions observed in the evidence, the data on semaglutide visceral fat reduction sets out those figures with appropriate context.

Eligibility, clinical assessment, and what to do next

Wegovy is a prescription-only medicine, assessed and prescribed according to clinical criteria. The MHRA licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, which can include type 2 diabetes, hypertension, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber also weighs up medical history, any contraindications and whether the medicine is appropriate for that individual. BMI and a self-assessed fat distribution are starting points, not a green light.

Accessing Wegovy through the NHS is possible for some patients through specialist weight-management services, though waiting lists can be lengthy. Our Wegovy overview explains both routes clearly. For people considering the private route, the cost of Wegovy varies by dose and provider, and is worth understanding before you start. You can also read more about weight-loss treatment options more broadly, or browse our FAQs if you have specific questions before starting.

If you think Wegovy might be right for you (whether your concern is visceral fat, overall weight, or the metabolic risks that come with carrying excess weight around the middle) the right starting point is a proper clinical assessment. Some people also wonder whether taking Wegovy for just a month is a realistic option, and that page addresses the question honestly before you commit. Check your eligibility with our prescribers, who review every consultation personally, the same day.